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INTRODUCTION
Motion sickness is observed in humans exposed
to unfamiliar motion (1-3). The characteristic symp-
toms and signs of motion sickness are nausea, vom-
iting, pallor and cold sweating. Virtually all humans
are susceptible to motion sickness on exposure to
unfamiliar motion of sufficient intensity and duration,
and many other animal species also exhibit suscep-
tibility.
The vestibular end-organs, the semicircular canals
and otolith organs, play a significant role in the genesis
of motion sickness (4). Many motions that cause
vigorous stimulation of the vestibular end-organs are
very effective in causing motion sickness. Patients
without vestibular function do not experience mo-
tion sickness. However, it is difficult to accept the
hypothesis that motion sickness is due to vestibular
overstimulation, because it does not account for space
motion sickness.
More than half of astronauts who have flown in
spacecrafts have experienced symptoms similar to
those that are characteristic of terrestrial motion
sickness (5, 6). Space motion sickness appears within
the first few hours in the microgravity environment,
but is not seen at launch, when the astronaut is ex-
posed to linear acceleration. Space motion sickness
is frequently precipitated by active head movement,
which does not produce terrestrial motion sickness.
These phenomena are clearly inconsistent with the
vestibular overstimulation hypothesis of motion sick-
ness. Nor can it account for visually-induced mo-
tion sickness, such as simulator sickness.
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of motion sickness is the most plausible (7-9). In
this review, the theoretical basis of the neural mis-
match model of motion sickness is presented. Based
on our results in experiments in a rat model, pro-
posed neural mechanisms of motion sickness in the
course of sensory processing, generating the neural
mismatch signal and the emetic linkage, and the
factors influencing susceptibility to motion sickness
are then presented. Finally, the prevention and treat-
ment of motion sickness are discussed.
AETIOLOGY OF MOTION SICKNESS
Essential to the neural mismatch hypothesis of mo-
tion sickness is the neural mismatch signal. The
converging sensory inputs from the otolith organs,
semicircular canals, eyes and somatosensory recep-
tors are mismatched with the expected sensory pat-
terns in the neural store calibrated by past experience,
and spatial orientation is disturbed, leading tomotion
sickness. The essential components of the neural
mismatch model of motion sickness are illustrated
in Fig. 1. When a body movement is commanded,
the efference copy is transmitted to the neural store
(memory directory) where it retrieves and reactivates
the stored afference previously associated with it
(expected afference). The function of the comparator
is to match the converging sensory inputs (re-afference)
with the expected afferenee selected from the neural
store by the efference copy. If there is a discrep-
ancy between the expected patterns and current inputs,
the mismatch signal is generated, triggering the neur-
almechanismsmediating autonomicnervous symptoms.
A component of the neural mismatch signal also up-
dates the neural store where a new association of
re-afference and efference copy is registered. When
the association is consolidated, the comparator accepts
the match, and the adaptation/habituation processes
are terminated. The neural mismatch hypothesis explains
many of the known characteristics of motion sickness,
including space motion sickness and visually-induced
motion sickness. It can be equally applicable in under-
standing such autonomic reaction as nausea and vom-
iting associated with pathological (e.g., Meniere’s
disease) or surgical (e.g., labyrinthectomy) disturbances
of vestibular function (10, 11).
NEURAL MECHANISMS OF MOTION SICKNESS
1. Emetic linkage and histamine
Antihistamines, which block histamine H1-receptors,
are effective in preventing motion sickness in humans
(12-14), but new H1-receptor antagonists such as
astemizole, which cannot cross the blood-brain bar-
rier, are not effective against motion sickness (15).
Fig.1. The neural mismatch hypothesis and neural mismatch mechanisms of motion sickness. HA : histaminergic neuron system ;
H1 : histamine H1-receptor ; Ach : cholinegic neuron system ; M : acetylcholine muscarinic receptor ; NA : noradrenergic neuron sys-
tem ; GABA : GABAergic neuron system ; GABAA : GABAA receptor.
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Therefore, the histaminergic neuron system in the
brain has been suspected to play an important role in
the neural processes of motion sickness. Takeda et al.
(16) and Morita et al . (17) developed a rat model of
motion sickness and examined the neuropharmacological
involvements of the histaminergic neuron system in
motion sickness. Rats cannot vomit, but pica, the in-
gestion of non-nutritive substances such as kaolin
(hydrated aluminum silicate), is an illness-response
behavior in rats, which is analogous to vomiting (18).
Morita et al. (17) showed that pica is an index of
motion sickness in rats. Rotation around two axes (double
rotation) with continuously changing centrifugal and
angular accelerations was found to induce kaolin in-
take in rats (Fig. 2a), suggesting that these rats suf-
fered from motion sickness. In contrast, after rota-
tion around one axis (single rotation), rats consumed
only a small amount of kaolin (Fig. 2b). Moreover,
double rotation did not increase kaolin intake in bi-
laterally labyrinthectomized rats. Since double ro-
tation presents an unusual pattern of sensory inputs
to the otolith organs and semicircular canals which
could cause neural mismatch, these findings dem-
onstrate that rats, like humans, suffer from motion
sickness due to the neural mismatch signal gener-
ated by the vestibular information passed through
the inner ear.
The double rotation-induced pica is suppressed
by diphenhydramine, an antagonist of H1-receptor,
showing that the histaminergic mechanisms involved
in human motion sickness are apparently also in-
volved in the development of motion sickness in rats
(19). However, the possibility that the prophylactic
effect of antihistamines is due to their anti-cholinergic
activity (13) cannot be excluded. Takeda et al. (16, 20)
used the rat model and found α-fluoromethylhistidine
(FMH), which is an irreversible inhibitor of the histidine
decarboxylase (HDC), is an effective anti-motion sick-
ness agent. FMH depletes brain neural components
of histamine and specifically blocks neural transduction
of the histaminergic neuron system (21). In rats treated
with FMH, double rotation-induced pica was suppressed,
suggesting that FMH prevents motion sickness in the
rat. FMH also suppresses motion-induced vomiting
in the cat (22) and the suncus (23). These findings
that FMH prevents motion sickness suggest that the
histaminergic neuron system is specifically involved
in the development of motion sickness.
Takeda et al. (16) examined the effects of double
and single rotation on the histaminergic neuron sys-
temic the rat model. Immunohistochemical studies
have demonstrated that histaminergic neurons are
concentrated in the hypothalamus, and the pons-medulla
oblongata, one of the most important regions of the
brain in motion sickness, contains histaminergic fi-
bers (24, 25). Double rotation significantly increased
Fig.2 a, b. Effects of double rotation (a) and single rotation (b) on histamine levels in the hypothalamus and pons-medulla
oblongata, and kaolin intake as an index of motion sickness in rats. Double rotation increased the histamine levels in these regions
and kaolin consumption. (From Takeda et al., 1986 (16) with permission)
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the histamine contents in both regions (Fig. 2a),
suggesting that double rotation, which produces mo-
tion sickness, changes the activity of the histaminergic
neuron system. On the other hand single rotation, which
does not induce motion sickness, does not increase
the histamine content of these regions (Fig. 2b). Re-
cently, using in vivo brain microdialysis technique,
Horii et al. (26) measured endogenous histamine re-
lease from the hypothalamus of rats during unilateral
caloric stimulation. Hot water irrigation of the middle
ear, which activates the lateral semicircular canal
afferents, increased histamine release from the hypo-
thalamus. However, ice water irrigation, which inhibits
the canal afferents, also increased histamine release
(Fig. 3). Thus, caloric stimulation both hot and cold
water activates the histaminergic neuron system in
the brain. Even though the initial causes of motion
sickness and of emesis induced by unilateral vestibu-
lar dysfunction (caloric stimulation) may differ, both
are considered to be generated by the neural mis-
match signal arising from mismatch of the converging
sensory inputs and expected sensory pattern (10,
11). Taken together with the neuropharmacological
finding that FMH prevents motion sickness, the
neurochemical findings therefore suggest that the
neural mismatch signal activates the histaminergic
neuron system, resulting in motion sickness.
Recently, Takeda et al. (27) developed an animal
model of space motion sickness. Uno et al. (28) used
the animal model and reported that histamine release
from the hypothalamus of freely moving rats exposed to
negative change in gravity with in vivo brain microdialysis
technique. It is suggested that histaminergic activation
in the development of motion sickness induced by
negative change in gravity is underlyingmechanisms
of space motion sickness.
According to the neural mismatch hypothesis, the
repeated arrivals of the neural mismatch signals update
the neural store, which registers a new re-afference
and efference copy association. The comparator then
accepts the match, and adaptation/habituation to the
provocative motion is acquired. Takeda et al . (29)
examined the effects of FMH on the development
of habituation to double rotation in rats. Based on
their hypothesized effects of anti-motion sickness drugs
on the development of habituation to provocative mo-
tion, they classified the anti-motion sickness drugs
into the following three classes : Class A drugs that
block the sensory input which is responsible for
neural mismatch ; Class B drugs thatmodify the neur-
al store to reduce the neural mismatch signal ; and
class C drugs that inhibit the subsequent mecha-
nisms which bring about the symptoms and signs of
motion sickness. While all these types of drugs have
protective effects against motion sickness, their ef-
fects on the development of habituation to provoca-
tive motion probably differ. It was hypothesized that
class A drugs would retard the acquisition of habitua-
tion, since they block the sensory input to be habitu-
ated (Fig. 4 a), Class B drugs would accelerate the
processes of habituation (Fig. 4b), and class C drugs
would not affect habituation, since they block only
the final processes in motion sickness (Fig. 4c). Rats
were rotated in the double rotation mode once a day
for 10 days. After day 8, kaolin intake gradually de-
creased with habituation to double rotation. On days
4 to 6, test animals were treated with FMH before
exposure to double rotation. Controls were received
Fig. 3. Effects of caloric stimulation on
histamine release from the hypothalamus
in rats. Irrigation with hot water or ice
water of the middle ear, but not that with
ice water of the auricle, increased the
histamine release. *p<0.05 vs. the release
before the evoked release. (From Horii
et al., 1993 (26) with permission)
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saline only. Although FMH decreased kaolin intake on
days 4 to 6, the residual habituation of the FMH-treated
rats at day 10 was almost the same as that of the con-
trol rats (Fig. 5). This finding indicates that the rate
of habituation in the rats that showed reduction of
motion sickness due to FMH was the same as that in
controls. Since the curve for the effect of FMHon the
development of habituation is similar to the solid line
in Fig. 4c, FMH is a class C drug. Therefore, it is sug-
gested that the histaminergic neuron system is in-
volved in the symptomatic mechanism of motion sick-
ness.
Immunohistochemical studies have demonstrated
that the histaminergic neurons are located in the
tuberomammillary nucleus (El-5) in the posterior
hypothalamus and that their axons project both
rostrally and causally (30). It has also been suggested
that the emetic center encompasses the neural interactions
among the parvicellular reticular formation, the nucleus
tractus solitarii, the dorsal motor nucleus of the vagi
and the nucleus ambiguous (31). Immunohistochemical
and autoradiographic studies have demonstrated that
histaminergic fibers (30) and H1-receptors (32) are
distributed in the emetic center. Bhargava et al.(33)
reported that the intracerebroventricular administration
of histamine in dogs caused vomiting via H1-receptors.
Fig.4 a, b, c. Hypothesized effects of drugs classes A, B and C on the development of habituation to provocative motion. In the
insert graphs (a, b and c) for drugs A, B and C, respectively, the solid line indicates the kaolin intake as an index of motion sickness
in rats treated with each drugs on the days indicated by arrows over daily rotations ; the dashed line shows the kaolin intake of con-
trols. (From Takeda et al., 1993 (29) with permission)
Fig.5. Effects of FMH on habituation to double rotation in highly
susceptible rats. ● : Rats with FMH ; ○ : Control rats. Although
FMH decreased kaolin intake on day 4 to 6, the rate of habitu-
ation in FMH-treated rats was the same as that in the controls.
(Data from Takeda et al., 1993 (29))
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Therefore, it seems likely that histaminergic descending
impulses induced by the neuralmismatch signal stimu-
late H1-receptors in the emetic center, resulting in
motion sickness (Fig. 1). The clinical observation
that H1-antagonists reduce the severity of motion sick-
ness symptoms, even if administered after nausea or
vomiting has developed (34), support the hypoth-
esis of histaminergic involvement in the mechanism
underlying the development of symptoms and signs
of motion sickness. The hypothesismay also account
for the oliguria associated with motion sickness. The
plasma vasopressin level is increased in humans suf-
fering from motion sickness (35), and histaminergic
fibers innervate the paraventricular nucleus, which
contains vasopressinergic neurons (36). Vasopressin
release can be increased by intracerebroventricular
administration of histamine, utilizing H1-receptor (37).
Therefore, it also seems likely that mismatch-induced
histaminergic ascending input to the paraventricular
nucleus causes the oliguria in motion sickness.
2. Mismatch signal and acetylcholine
The efficacy of scopolamine, an antagonist of
acetylcholine muscarinic receptors, has been shown
to prevent motion sickness in humans (12-14). Ac-
cordingly, acetylcholine has been considered to be one
of the most important neurotransmitters involved in
motion sickness. Morita et al. (38) used the rat model
of motion sickness and examined the effect of sco-
polamine on the development of habituation to motion.
Rats were rotated in the double rotation mode once
a day for more than 10 days. Rats treated with one
eighth of a clinical-sized patch of TTS (transdermal
therapeutic system)-scopolamine on days 4 to 7 showed
progressive decrease of kaolin intake after double
rotation, which is an index of motion sickness of rats.
When the TTS-scopolamine patch was removed just
after rotation on day 7, the residual habituation was
more marked than that in the control rats. On day
10, the kaolin intake was still decreased relative to
that of the controls (Fig. 6). These findings demon-
strate that scopolamine accelerated the processes of
habituation to double rotation and is a class B drug
(solid line in Fig. 4b). Conversely, physostigmine, a
centrally acting cholinesterase inhibitor which increases
cholinergic transmission in the brain, was found to
delay habituation to double rotation in rats, while the
cholinesterase inhibitor neostigmine, which does not
act centrally, had no such effect (38). In humans,
scopolamine buthylbromide, which cannot cross the
blood-brain barrier, is ineffective against motion sick-
ness (12). All of these findings suggest that the
cholinergic neuron system in the brain is involved
in the processes of habituation to motion sickness.
TTS-scopolamine affords better protection against
sea sickness when the period of exposure is longer
(39). Clinical trials of long-term use of TTS-scopolamine
to prevent sea sickness indicate that its benefical ef-
fect is increased when it is applied in the early stage
of the trip, before adaptation occurs (40). These clini-
cal observations are consistent with the experimen-
tal conclusion that scopolamine facilitates habituation
Fig.6. Effects of TTS-scopolamine on habituation to double rotation in highly susceptible rats. ● : Rats with TTS-scopolamine ; ○ :
Control rats. TTS-scopolamine decreased kaolin intake on day 4 to 7. After the TTS-scopolamine patch removed, the kaolin intake of
treated rats remained lower than that in the controls. (From Morita et al., 1990 (38) with permission)
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to the provocative motion. However, Wood et al. (41)
reported a controversial set of results regarding the
effects of scopolamine on habituation to rotation in
humans : the drug was found to accelerate habituation,
but a rebound of sensitivity to vestibular stimulation
was observed after withdrawal of scopolamine. On
the other hand, the clinical finding that scopolamine
is much less effective when administered after symp-
toms have appeared (42) may exclude cholinergic
involvement in the symptomatic mechanism of mo-
tion sickness.
The two main cholinergic pathways in the brain
are the projection from the magnocellular forebrain
nuclei to the cerebral cortex and the septo-hippocampal
pathway (43, 44). The cerebral cortex and limbic sys-
tem, particularly the hippocampus, are major sites of
spatial orientation information processing (45, 46).
It has been shown that the hippocampal cholinergic
neuron is activated by auditory and somatosensory
stimulation, while the cortical cholinergic system is
unaffected (47). Recently, Horii et al . (48) using in
vivo brain microdialysis technique, demonstrated that
electrical vestibular stimulation increases the release
of acetylcholine from the hippocampus. Thus, the
cholinergic septo-hippocampal pathways have an im-
portant role in sensory input processing (49).
Although the neural mismatch signal is generated
in the region of the brain subserving spatial orien-
tation, the anatomical location is unknown (50-52).
Several lines of evidence suggest that the hippocampus
can process both spatial and nonspatial information
(53). The sensory information processing in the
hippocampus, in which novel information is compared
with the stored sensory memory (54), seems likely
to be responsible for the generation of the neural mis-
match signal. Moreover, O’Keefe (55, 56) found “place
units” in the hippocampus, which are strongly cor-
related with the animal’s location and proposed the
hypothesis that the hippocampus contains a spatial
map. There may be an analogy between the neural
store and the spatial map in the hippocampus.
Several lines of evidence suggest that the cholinergic
neuron system in the hippocampus is involved in
learning and memory (57). In a recently proposed
model of cholinergic modulation of cortical associa-
tive memory function, activation of the cholinergic
system facilitates the acquisition of associative memo-
ry by enhancing a new input pattern and suppressing
previous stored patterns (58, 59). The model can be
applied to the neural mismatch hypothesis of motion
sickness. The cholinergic neuron system activated
by the neural mismatch signal stimulates the acqui-
sition of a new pattern of re-afference and efference
copy, resulting in the development of adaptation/
habituation (updating the neural store) (Fig. 1). In
fact, Horii et al. (48) demonstrated that both uni-
lateral stimulation of the canal by hot water irrigation
of the middle ear and unilateral suppression of the
canal by ice water increased the acetylcholine re-
lease from the hippocampus (Fig. 7), suggesting that
the neural mismatch signal activates the hippocampal
cholinergic neuron system.
The model also indicates that cholinergic antagonists
would impair the discrimination of stored sensory
patterns (58, 59). In the case of scopolamine, the drug
would prevent identification of the expected afference
previously associated with efference copy from the neur-
al store. Re-afference without the expected afference
Fig. 7. Effects of caloric stimulation on
acetylcholine release from the hippocampus
in rats. Irrigation with hotwater or ice water,
but not that with 37℃ water, of the middle
ear increased the acetylcholine release.
*p<0.01 vs. the release before the evoked
release. (From Horii et al., 1994 (48) with
permission)
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does not activate the comparator nor generate the
neural mismatch signal. Thus, it is likely that sco-
polamine prevents motion sickness by reducing the
neural mismatch signal (Fig. 1). In the adaptation/
habituation processes inmotion sickness, unpredictable
passive motion generates the neural mismatch signal,
which updates the neural store. On the other hand,
during the acquisition of motor skills and control in
early childhood, the newly acquired but as yet un-
familiar locomotion does not generate the neural mis-
match signal, because the expected afference asso-
ciated with the efference copy of the locomotion
command is not yet available in the neural store.
Re-afference without the neural mismatch signal would
be directly registered in the neural store in associa-
tion with the efference copy, leading to the develop-
mental acquisition of locomotion observed in infancy.
If the suggestion that scopolamine reduces the neural
mismatch signal is correct, then the neural store ac-
quisition of a new association of re-afference and
efference copy induced by scopolamine would more
rapid than that resulting from mismatch-induced
updating. Thus, the cholinergic model of associative
memory could also account for the prevention of
motion sickness and facilitation of the processes of
adaptation/habituation induced by scopolamine.
The ventral tegmental nucleus (VT) is a midbrain
core structure of the limbic system and is respon-
sible for the transfer of sensory information arising
from the brain stem to limbic forebrain structures
(60). Irle et al . (61) reported monosynaptic inner-
vation from the vestibular nuclei to the VT in mice,
rats and cats. Therefore, vestibular information may
enter the hippocampus via the VT. On the other hand,
Erickson et al . (62) reported that the afferent con-
nections of the hypothalamic tuberomammillary nu-
cleus, which contains histaminergic neurons, arise
from the limbic system. This pathway may transmit the
neural mismatch signal generated in the hippocampus
to the hypothalamic histaminergic system as the trig-
ger in the emetic linkage processes. Preliminary
experiments have demonstrated that AF64A, which
degenerates cholinergic neurons, suppresses the
vestibular-evoked histamine release fromhypothalamus,
while depletion of histamine by FMH does not affect
acetylcholine release from the hippocampus induced
by vestibular stimulation in rats (63). The findings
suggest transmission from cholinergic to histaminergic
processes in the development of motion sickness.
Another candidate as the comparator and neural
store is the cerebellum, which receives signals from
the vestibular nuclei and other sensory inputs (52).
Recent immunohistochemical study demonstrated
that cholinergic mossy afferents to the vestibular
cerebellum arise from the medial vestibular nucleus
and prepositus hypoglossal nucleus (64). Sincemuscarinic
receptors are concentrated in the vestibular cerebel-
lum (65), scopolamine as an anti-motion sickness
drug may act on the cerebellum.However, it is unclear
whether the cerebellum is (66) or is not (67) essen-
tial in the development of motion sickness. Recently,
Uno et al. (68) used a rat model of motion sickness
and examined the effects of vestibular cerebellum
lesion on the development of motion sickness. Their
findings that surgical ablation of the bilateral cerebellar
flocculus and the cerebellar vermis had no effects
indicated that the vestibular cerebellum does not play
an essential role in the development of motion sick-
ness.
3. Sensory processing and noradrenaline
Amphetamine is used clinically as an anti-motion
sickness drug (12-14), and has also been observed
to prevent motion-induced pica as an index of motion
sickness in rats (19). Because amphetamine activates
the catecholaminergic neuron system with resulting
increase in the release of noradrenaline and dopamine
from the nerve terminals (69), the noradrenergic and
dopaminergic neuron system in the brain has been
thought to contribute to the therapeutic effect of am-
phetamine on motion sickness. Wood and Graybiel
(13) have hypothesized that the action of noradrenergic
neuron system in the brain is antagonistic to the de-
velopment of motion sickness. However, there is no
direct evidence for their hypothesis. Takeda et al .
(70) used the ratmodel to examine the neurochemical
effects of motion sickness-inducing rotational stimu-
lation on the activity of the noradrenergic neuron sys-
tem in the brain stem. They found that both single and
double rotation increased the turnover of noradrenaline,
suggesting that rotational stimulation activates the
noradrenaline system in the brain stem. However, as
double rotation induces motion sicknesswhereas single
rotation does not, increased noradrenergic activity
in the brain stem seems unlikely to be directly related
to the development ofmotion sickness. These findings
do not support the hypothesis of Wood and Graybiel
(13). Histochimical studies indicate that the vestibular
nuclei and brain stem reticular formation contains only
a few noradrenergic fibers (25, 71). Electrophysiologically,
conditioning stimulation of the locus coeruleus (LC),
which is the largest nucleus of central noradrenergic
neurons in the brain, has no effect on the neural ac-
tivity in the lateral vestibular nucleus in cats (72). These
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findings are further evidence that the noradrenergic
neuron system in the brain stem is not important in
the development of motion sickness.
Recently, Nishiike et al. (73) recorded the electri-
cal activity of noradrenergic neurons of the LC in rats
and examined the effects of unilateral caloric stimu-
lation on their activity. Both activation of the canal by
hot water irrigation and inhibition by cold water irriga-
tion suppress LC neuronal activity (Fig. 8). On the other
hand, it has been reported that noradrenergic neurons
in the LC are periodically activated during sinusoidal
body tilt in cats (74). Since unilateral caloric stimu-
lation causes nausea and vomiting like the symptoms
of motion sickness, while sinusoidal body tilt does
not, it is suggested that the neural mismatch signal
suppresses the noradrenergic neurons of the LC
(Fig. 1). Nishiike et al . (73) also reported that the
inhibitory response of LC neurons to caloric stimulation
is blocked by iontophoretic application of bicuculline,
a GABAA-receptor antagonist, indicating that the in-
hibition of LC neurons by caloric stimulation is mediated
by GABAA-receptors. Anatomical and electrophysiological
studies have demonstrated GABAergic input from
the prepositus hypoglossal nucleus (PrH) to the LC
via GABAA-receptors (75, 76). Since PrH neurons re-
ceive vestibular input, it is possible that GABAergic
neurons in PrH contribute to the LC neuronal inhi-
bition. However, the possibility is unlikely, because
lesions in PrH did not attenuate the inhibitory re-
sponse of LC neurons induced by caloric stimulation
(77). Another major input to the LC is the pathway
from the ventrolateral medulla (VLM) (75, 76). Re-
cently, Nishiike et al. (78) reported that electrical and
chemical lesions in VLM attenuated the LC inhibi-
tion in response to caloric stimulation, suggesting
that VLM is the origin of inhibitory vestibular input to
the noradrenergic neurons in LC. Therefore, it is sug-
gested that the neural mismatch signal activates the
VML, leading to inhibition of noradrenaline-containing
LC neurons via GABAA-receptors (Fig. 1).
In addition to nausea and vomiting, drowsiness is
an important symptom commonly associated withmo-
tion sickness. A symptom complex concerning around
drowsiness has been termed the sopite syndrome (79).
Drowsiness of the sopite syndrome of motion sick-
ness persists long after the nausea and vomiting have
subsided. The LC participates in inducing arousal (80).
The long-lasting inhibition of LC neurons is induced
by caloric vestibular stimulation (73). Therefore, the
suppression of the noradrenergic neuron system
during vestibular stimulation may account for the
sopite syndrome.
In addition to amphetamine, central nervous system
stimulants, which facilitate noradrenergic transmission,
such as pemolin and methylphenidate, are also ef-
fective in preventing motion sickness (81). Nonspecific
sources of arousal, which activate the noradrenergic
neuron system, are also effective (1). Therefore, it is
likely that amphetamine or other psychostimulants
antagonize mismatch-induced suppression of the
noradrenergic neuron system and induce recovery
of the arousal state, resulting in prevention of motion
sickness.
Why does the neural mismatch signal suppress
the noradrenergic neuron system? Electrophysiological
studies have demonstrated that LC neurons are ac-
tivated by many kind of sensory stimuli, including
visual, auditory and somatosensory stimuli (82). This
broad spectrum of sensory responses, together with
the widespread efferent projections from the LC, sug-
gests that the noradrenergic neuron system plays an
important role in central sensory information processing.
Moreover, recent studies have suggested that LC neur-
ons are involved in the selective attention in selective
sampling of sensory stimuli (83). According to an evo-
lutionary hypothesis of motion sickness (84), the
mechanisms underlying motion sickness constitute
a warning system, which protects the body against
neurotoxins, such as toadstool. Treisman (84) postu-
lates that absorbed neurotoxins affect sensory inputs
or motor coordination, leading to generation of the
neural mismatch signal. An emetic response as a pro-
tective reflex would be induced by neurotoxins in-
gested by chance, but also inadvertently by provoca-
tive stimuli, such as vehicular travel. If this suggestion
is correct, suppression of the noradrenergic neuron
system induced by the neural mismatch signal would
shift attention from discordant sensory inputs, which
Fig.8. Effects of caloric stimulation on the neural activity of
the locus coeruleus (LC) in rats. LC neural activity was suppressed
in response to both hot and cold water irrigation of the middle
ear.
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are not novel stimuli to be attended, but disturbances
to be ignored.
Dopamine D2-receptor in the chemoreceptor trigger
zone (CTZ) in the area postrema has been estab-
lished to play a role in vomiting and nausea (85)
(Fig. 9). Domperidone and metochropramide, which
are D2-antagonists, inhibit emesis by inhibiting the
CTZ. However, these D2-antagonists have no effect
on motion sickness in humans (86) or in rats (87).
Nevertheless, the possibility of the involvement of
the dopaminergic neuron system in motion sickness
cannot be excluded, because amphetamine, an effective
anti-motion sickness drug, enhances dopaminergic
transmission as well as noradrenergic transmission
(69). Takeda, et al . (70) examined the effect of ro-
tation on the turnover of dopamine in the rat brain
stem. Both double rotation, which induces motion
sickness, and single rotation, which do not, increased
the turnover of dopamine. Thus, the dopaminergic
neuron system in the brain stem seems unlikely to
play a role in motion sickness.
INDIVIDUAL SUSCEPTIBILITY
Considerable individual differences have been found
in susceptibility to motion sickness upon exposure
to provocative motion (1, 2). In the general popula-
tion, age and sex are known to contribute to this
variation in susceptibility : motion sickness is rare
in those below the age of 2 years and above the age
of 50 years, but is more common in women than in
men of the same age. However, there are also indi-
vidual differences in susceptibility within groups of
men or women of the same age.
Three hypothetical factors, i.e., receptivity, adapt-
ability, and retentivity, have been proposed to ac-
count for variation in susceptibility to motion sick-
ness (88) (Table 1). Receptivity refers to the processing
of information in the brain. In persons with high re-
ceptivity, transduction and processing of sensory
stimuli are thought to bemore effective. Hence, when
receptive individuals are exposed to provocative mo-
tion, the intensity of the neural mismatch signal is
thought to be greater, with greater likelihood of develop-
Fig.9. Neuropharmacological mechanisms underlying the emetic reflex. CTZ : chemoreceptor trigger zone ; H1 : histamine H1-receptor ;
D2 : dopamine D2-receptor ; 5HT1A : serotonin 5HT1A-receptor ; 5HT3 : serotonin 5HT3-receptor. (From Takeda et al., 1993 (29)
with permission)
Table 1. Factors influencing individual differences of suscep-
tibility to motion sickness
1. Receptivity
2. Adaptability
3. Retentivity
4. Sensitivity of the emetic center
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ment of motion sickness than that in non-receptive
individuals. Adaptability refers to the rate at which
the individual adapts to provocative motion. Those
who low adaptability would be more likely to suffer
from motion sickness than those with high adapt-
ability. Retentability refers to the duration of retention
of adaptation after exposure to provocative motion.
Having once adapted to provocative motion, persons
with high retentability would remain less susceptible
than those with low retentability. Hasegawa et al. (89)
added recently the sensitivity of the emetic center as
another factor which may influence susceptibility to
motion sickness (Table 1). They found a wide vari-
ation in susceptibility to motion sickness using the
rat model. They then found significant positive corre-
lations between susceptibility to motion sickness and
to emesis induced by apomorphine and copper sulfate.
Since motion, apomorphine and copper sulfate in-
duce emesis through different receptors (Fig. 9),
the findings suggest that the sensitivity of a common
locus of emesis, presumably the emetic center in the
brain stem, is one determinant of individual differ-
ences in susceptibility tomotion sickness.When exposed
to many kinds of emetic stimuli, including provoca-
tive motion, persons with high sensitivity of the emetic
center may have low threshold for the emetic response,
andmay vomit or feel nauseamore frequently than persons
with low sensitivity. Clinically, Morrow (90) reported
that patients with a history of motion sickness were
significantly more susceptible to chemotherapy-induced
nausea and vomiting than those without such a histo-
ry. These four factors may all contribute to various
degrees to the susceptibility to motion sickness of
a given individual.
PREVENTION AND TREATMENT
The development of motion sickness involves the
three steps of sensory processing, generation of the
neural mismatch signal, and the emetic linkage. Block-
ade of any step can be used to prevent or treat mo-
tion sickness (Table 2).
1. Blockade of the emetic linkage
Antihistamines (H1-antagonists) have been dem-
onstrated to be effective in preventing and control-
ling motion sickness. The effective dose is 50 mg for
diphenhydramine or 25 mg for promethazine (13).
Since the histaminergic neuron system is involved
in the symptomatic mechanism of motion sickness
via H1-receptors, antihistamines reduce the severity
of the symptoms and signs of motion sickness by
blocking the emetic linkage between the neural mis-
match signal and the emetic center (Figs. 1 & 9).
Therefore, antihistamines are effective, even if ad-
ministered after nausea or vomiting has developed.
The side effect of antihistamines at effective dose is
sedation, which is to be avoided in crew-members
but may be useful in passengers.
If an anti-emetic drug inhibits the emetic center
itself, it would be effective in preventing emesis due
to all causes, including motion sickness. It is con-
ceivable that diphenidol may be a drug of this kind
(Fig. 9). Takeda et al. (91) demonstrated that diphenidol
suppressed all motion-, apomorphine and cisplatin-induced
pica analogous to emesis in rats. Diphenidol is clini-
cally effective in preventing motion sickness (13)
and emesis induced by levodopa, which acts on the
CTZ (92). Diphenidol has also been found to be ben-
eficial in patients receiving cisplatin (93). However,
the specific receptor for diphenidol remains unknown.
Diphenidol used at the dose of 50 mg is as effective
as antihistamines. Lucot & Crampton (94) have shown
that 8-OH-DPAT, a serotonin 5HT1A-receptor agonist,
suppressed the vomiting induced by motion, cisplatin,
and xylazine in cats, suggesting that this agent acts
on the emetic center (Fig. 9). However, the efficacy
in motion sickness of buspirone, a clinically used
5HT1A agonist, has not been reported.
Dopamine D2-receptor antagonists such as domperidone
and metochropramide are clinically used as anti-emetic
drugs. D2-antagonists inhibit emesis by inhibiting the
CTZ in the area postrema. However, these D2-antagonists
have no effect on motion sickness in humans (86)
or in rats (87). Serotonin 5HT3-receptor antagonists
such as ondansetron and granisetron are effective
for preventing emesis induced by anti-cancer therapy
(95). However, 5HT3-antagonists have no prophylactic
effect against motion-induced emesis in humans (96)
and rats (97). Thus, H1-, D2- and 5 HT3-receptors are
Table 2. Prevention and treatment of motion sickness
1. Blockade of the emetic linkage
Antihistamines (H1-receptor antagonist), diphenidol
2. Reduction of mismatch signal size
TTS-scopolamine
Training for adaptation to provocative motion
3. Modification of sensory input
Restriction of head movement
Learned postural adjustment
Avoidance of discordant visual cue
Amphetamin or other psychostimulants
N. Takeda et al. Neural mechanisms of motion sickness５４
independently involved in the emetic reflex (Fig. 9).
2. Reduction of mismatch signal size
Scopolamine has been shown to have a prophylactic
effect against motion sickness, but it is less useful in
controlling established motion sickness. Scopolamine
administered orally or intramuscularly is less effective,
because of its short half-life in the serum. The dis-
advantage has been overcome with the development
of a transdremal therapeutic system for administration
of scopolamine in the form of TTS-scopolamine (97).
The effect of TTS-scopolamine is like that of continu-
ous intravenous infusion : scopolamine is released
into the systemic circulation gradually and an effec-
tive serum concentration is maintained. The incidence
of side effects (such as dry mouth and drowsiness
etc.) associated with TTS-scopolamine is lower than
that associated with orally or intramuscularly admin-
istered scopolamine, and it is equally efficacious in
preventing motion sickness. The cholinergic model
of associative memory suggests that scopolamine
prevents motion sickness by reducing the neural
mismatch signal and by facilitating the adaptation/
habituation processes. Therefore, scopolamine should
be administrated prior to exposure to provocative
motion to obtain better protection.
The most potent therapeutic measure, at least in
the long term, is adaptation to the provocative motion,
and it is the preferred method of preventing motion
sickness, particularly for crew-members (2, 98). For
the acquisition and maintenance of protective adap-
tation, the individual should be gradually exposed to
the provocative motion. Once adaptation is achieved,
regular and repeated exposure to the motion stimuli
should be maintain. Anti-motion sickness drugs, es-
pecially scopolamine, may aid the adaptation method
by accelerating the acquisition of protective adap-
tation.
3. Modification of sensory input
Some behavioral measures prevent motion sick-
ness by modifying the sensory pattern, which is re-
sponsible for the neural mismatch signal. Head
movement should be reduced to a minimum. The
restriction of head movements during acceleration
in vehicles helps to prevent motion sickness because
additional complex set of stimulation, such as cross-coupled
acceleration, are avoided. Learned postural adjustment,
which counter-regulates the body oscillations induced
by vehicular acceleration, is also helpful (99). Dis-
cordant visual cues should also be minimized. For
example, reading a book or looking at a map in a
moving vehicle should be avoided, because visual/
vestibular conflict inputs are responsible for the neur-
al mismatch signal.
Amphetamine and psychostimulants have been
demonstrated to be effective in preventing motion
sickness. In particular, the combination of metham-
phetamine with scopolamine (13) or with promethazine
(14) is the most effective for prophylaxis. It is sug-
gested that general arousal activated by ampheta-
mine prevents motion sickness. Amphetamine is es-
pecially effective in relieving the drowsiness of sopite
syndrome of motion sickness (100).
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